Changing Paradigms in Clinical Oncology Research — Highlights from the 2011 ASCO Annual Meeting and Beyond

References

1. ↵
   ASCO proceeding, 2011.
2. ↵
   1. Walker I. &
   2. Newell H.

   Do molecularly targeted agents in oncology have reduced attrition rates? Nature Rev. Drug Discov, 2009; 8: 15–6.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Solit DB,
   2. Tangen C, and
   3. Lara PN. Jr.

   Developing and implementing more informative phase II oncology trials. ASCO educational book 2011; 84–88.
4. ↵
   1. Sharma MR,
   2. Stadler WM, and
   3. Ratain MJ.

   Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011; 103: 1093–100.

   OpenUrlCrossRefPubMed
5. ↵
   ASCO online abstract database 2007–2011 (http://www.asco.org/ASCOv2/Meetings/Abstracts).